Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Raises $66.9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Intrexon has raised $66.9 million, according to a document filed with the US Securities and Exchange Commission last week.

Based in Blacksburg, Va., the genetic engineering firm did not say how the funds will be used but said the offering was not made in connection with a business combination transaction such as a merger.

A total of 82 investors participated in the offering, though Intrexon did not identify them. The company, which had been called Genomatix, said the date of the first sale for the offering was Feb. 19, 2010.

A company spokesman declined to comment on the transaction.

In January 2010, Intrexon raised $25 million in equity financing.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.